Mineralys Therapeutics (MLYS) Cash from Investing Activities (2022 - 2026)
Quarterly results put Cash from Investing Activities at -$44.9 million for Q1 2026, up 51.61% from a year ago — trailing twelve months through Mar 2026 was -$341.8 million (down 538.03% YoY), and the annual figure for FY2025 was -$389.8 million, down 439.04%.
Mineralys Therapeutics has reported Cash from Investing Activities over the past 5 years, most recently at -$44.9 million for Q1 2026.
- Cash from Investing Activities reached -$44.9 million in Q1 2026 per MLYS's latest filing, up from -$103.5 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $83.6 million in Q4 2024 and bottomed at -$150.5 million in Q3 2025.
- Median Cash from Investing Activities over the past 5 years was -$42.9 million (2025), compared with a mean of -$33.5 million.
- The largest annual shift saw Cash from Investing Activities skyrocketed 1886.65% in 2024 before it crashed 654.3% in 2025.
- Over 5 years, Cash from Investing Activities stood at $50.0 million in 2022, then tumbled by 116.18% to -$8.1 million in 2023, then surged by 1133.13% to $83.6 million in 2024, then crashed by 223.84% to -$103.5 million in 2025, then skyrocketed by 56.57% to -$44.9 million in 2026.
- Business Quant data shows Cash from Investing Activities for MLYS at -$44.9 million in Q1 2026, -$103.5 million in Q4 2025, and -$150.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | -2.89 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 638.50 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | -431.90 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | -428.90 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Mineralys Therapeutics | 2.50 Bn | 2.50 Bn | - | -44.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -44.94 Mn |
| Mar 31, 2026 | -44.94 Mn |
| Dec 31, 2025 | -103.49 Mn |
| Dec 31, 2025 | -103.49 Mn |
| Sep 30, 2025 | -150.51 Mn |
| Sep 30, 2025 | -150.51 Mn |
| Jun 30, 2025 | -42.88 Mn |
| Jun 30, 2025 | -42.88 Mn |
| Mar 31, 2025 | -92.88 Mn |
| Mar 31, 2025 | -92.88 Mn |
| Dec 31, 2024 | 83.57 Mn |
| Dec 31, 2024 | 83.57 Mn |
| Sep 30, 2024 | 79.61 Mn |
| Sep 30, 2024 | 79.61 Mn |
| Jun 30, 2024 | 7.74 Mn |
| Jun 30, 2024 | 7.74 Mn |
| Mar 31, 2024 | -55.95 Mn |
| Mar 31, 2024 | -55.95 Mn |
| Dec 31, 2023 | -8.09 Mn |
| Dec 31, 2023 | -8.09 Mn |
| Sep 30, 2023 | 4.01 Mn |
| Sep 30, 2023 | 4.01 Mn |
| Jun 30, 2023 | -16.14 Mn |
| Jun 30, 2023 | -16.14 Mn |
| Mar 31, 2023 | -140.25 Mn |
| Mar 31, 2023 | -140.25 Mn |
| Dec 31, 2022 | 50.00 Mn |
| Dec 31, 2022 | 50.00 Mn |
| Sep 30, 2022 | -71.76 Mn |
| Sep 30, 2022 | -71.76 Mn |